IP Library Granted Patent US 11,166,968
Granted Patent B2
US 11,166,968 · App. 15/758,535 · Granted Nov 9, 2021

Synergistic composition for maintenance of healthy balance of microflora

Inventors: Jingru Li (Milton, GA); Lindsay Adrienne Peed (Peachtree Corners, GA); Cheryce Francina Joyner (Tallahassee, FL); Rebecca Ann Vongsa (Neenah, WI); David William Koenig (Menasha, WI); Ryan Daniel Bartell (Appleton, WI); Paige Nicole Hollmaier (Neenah, WI)
Assignee: Kimberly-Clark Worldwide, Inc.
A61K31/7004A61K9/0034A61K31/194A61K31/70A61K31/7016A61K31/724A61P15/02A61K31/732A61K31/733A61K2300/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,166,968
App. No.
15/758,535
Granted
Nov 9, 2021
Kind
B2
Abstract

The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of treating and preventing vaginal infections. Compositions useful in supporting healthy microflora, disclosed herein, generally comprise a therapeutic amount of a first saccharide and a therapeutic amount of a second saccharide or an organic acid. The saccharides may be, for example, a pentose, a disaccharide, a cyclodextrin, a pectic substance or a non-digestible polysaccharide. The organic acid may be, for example, malic acid.

Claims (4)

1. A composition comprising a first therapeutic agent comprising 2-Deoxy-D-Ribose and a second therapeutic agent comprising lactulose, wherein the composition synergistically promotes the growth of L. crispatus relative to E. coli such that the therapeutic effect is greater than about 30.

2. The composition of claim 1 wherein the weight ratio of the first therapeutic agent and the second therapeutic agent is from about 1:1 to about 1:50.

3. The composition of claim 1 wherein the first therapeutic agent comprises from about 0.1 to about 2.0 wt/v %, the second therapeutic agent comprises from about 0.1 to about 2.0 wt/v %.

4. The composition of claim 1 wherein the first therapeutic agent and the second therapeutic agent in combination comprise a total of about 5% wt/v %.

Continuity (1)
Related Publication 20180250318A1 · Sep 6, 2018